# Re-evaluation Task: LUN-008

## Context
- **Case ID**: LUN-008
- **Cancer type**: Non-Small Cell Lung Cancer (NSCLC) — RET Fusion-Positive Adenocarcinoma
- **Stage**: Stage III
- **Molecular profile**: RET fusion-positive
- **Report file**: experiment_reports\LUN-008_report.json
- **Current score**: 85/100
- **Gap analysis (local GPU)**: The most critical gaps in the LUN-008 cancer research report are the lack of data on Selpercatinib's efficacy as a first-line monotherapy and its use in adjuvant therapy post-surgery, which will be addressed by filling these intent missing sections to provide more comprehensive insights into treatment outcomes. Filling these gaps will improve the score by providing a more complete understanding of Selpercatinib's effectiveness in different clinical scenarios, allowing for more informed decision-making in cancer treatment.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  13/25  |  52.0% |
| rating_calibration                  |  13/15  |  86.7% |
| clinical_relevance                  |   9/10  |  90.0% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (52.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\LUN-008_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Non-Small Cell Lung Cancer (NSCLC) — RET Fusion-Positive Adenocarcinoma",
    "stage": "Stage III",
    "molecular_profile": [
      "RET fusion-positive"
    ],
    "patient_info": {
      "case_id": "LUN-008",
      "age": 45,
      "sex": "Male",
      "ecog_status": 0,
      "risk_factors": [
        "Family history of cancer"
      ],
      "comorbidities": [
        "Chronic kidney disease stage 2"
      ]
    }
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Selpercatinib (Retevmo) — First-Line Monotherapy",
      "category": "Approved Targeted Therapy",
      "composite_rating": 9.4,
      "rating_breakdown": {
        "evidence_level": {
          "score": 10,
          "rationale": "Phase 3 RCT (LIBRETTO-431) demonstrated superiority over chemotherapy +/- pembrolizumab in first-line RET fusion-positive NSCLC with PFS HR 0.46 (p<0.001). Supported by Phase 1/2 LIBRETTO-001 with long-term follow-up."
        },
        "survival_benefit": {
          "score": 9,
          "rationale": "Median PFS 24.8 months vs 11.2 months (HR 0.46). ORR 84% vs 65%. Median DoR 24.2 months vs 11.5 months. LIBRETTO-001 final OS 47.6 months in pretreated patients. More than doubles PFS vs standard chemotherapy."
        },
        "accessibility": {
          "score": 10,
          "rationale": "FDA approved (September 2022 for first-line RET fusion-positive NSCLC). Also EMA approved. Widely available at major cancer centers. Oral administration."
        },
        "safety_profile": {
          "score": 8,
          "rationale": "Generally well tolerated. Grade >=3 TRAEs: hypertension (13%), ALT increase (9%), AST increase (6%). Only 3% treatment discontinuation in LIBRETTO-001. Important for CKD patients: selpercatinib causes pseudo-decrease in kidney function by inhibiting tubular creatinine secretion (MATE1 inhibition) — use cystatin C for true renal monitoring."
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "Directly targets the patient's confirmed RET fusion. Selpercatinib is a highly selective RET kinase inhibitor with IC50 of 0.8 nM. Perfect biomarker match for RET fusion-positive adenocarcinoma."
        }
      },
      "mechanism_of_action": "Selpercatinib is a highly selective, ATP-competitive small molecule inhibitor of the RET receptor tyrosine kinase. It inhibits wild-type RET and multiple mutant RET isoforms including RET fusions (KIF5B-RET, CCDC6-RET), blocking downstream signaling through RAS/MAPK and PI3K/AKT pathways that drive tumor cell proliferation and survival.",
      "key_evidence": {
        "study_name": "LIBRETTO-431",
        "journal": "New England Journal of Medicine",
        "year": 2023,
        "sample_size": 261,
        "os_months": {
          "treatment": 0,
          "control": 0,
          "hazard_ratio": 0,
          "p_value": 0
        },
        "pfs_months": {
          "treatment
... (truncated — read full file from experiment_reports\LUN-008_report.json)
```
